No Data
No Data
Lake Street Sticks to Its Buy Rating for Checkpoint Therapeutics (CKPT)
Express News | Checkpoint Therapeutics Announces $12 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules
Express News | Checkpoint Therapeutics Announces Biologics License Application Resubmission for Cosibelimab
Express News | Checkpoint Therapeutics Shares Are Trading Higher After the Company Announced It Reached Alignment With the FDA on Its on Its Biologics License Application Resubmission Strategy for Cosibelimab
Checkpoint Therapeutics Plans to Resubmit Application for Cancer Treatment Candidate
Checkpoint Therapeutics (CKPT) said Monday it plans to move forward with a mid-year resubmission of the biologics license application for its cosibelimab immunotherapy candidate to treat certain forms
Lake Street Maintains Checkpoint Therapeutics(CKPT.US) With Buy Rating
Lake Street analyst Thomas Flaten maintains $Checkpoint Therapeutics(CKPT.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 34.1% and a total average return of -9.6%
No Data